About Nexium NEXIUM is used for treating frequent.

Patients will be considered impaired when they are 60 and over , or if they have a history of previous gastric ulcer. The most commonly reported adverse events with NEXIUM include headache, diarrhea and abdominal pain. For full prescribing information for NEXIUM please visit.. About Nexium NEXIUM is used for treating frequent, persistent heartburn and other symptoms associated with acid reflux syndrome. Nexium is approved for the healing and maintenance of erosive esophagitis. Most erosions heal in 4 to 8 weeks. Individual results may vary, and only a doctor can determine, neuroscience the esophagus have occurred. Symptom relief not from the existence of other serious stomach conditions. Nexium is also used for reducing the risk of gastric ulcers develop indexed under at-risk patients on continuous NSAID therapy.

For more information about AstraZeneca, please visit:B RRX Medical, today announced the initiation of a landmark human study entitled ‘ablation of intestinal metaplasia containing dysplasia: a multicenter, randomized, placebo-controlled trial. ‘the AIM dysplasia Trial compare the efficacy of the HALO360 system against the current standard of treatment for Barrett’s esophagus, which includes regular endoscopic biopsy surveillance and appropriate medical management of associated acid reflux disease . Barrett’s esophagus, chronic chronic GERD, is a precancerous condition of the lining of the esophagus approximately three million about three million adults in the United States. Barrett’s patients are at an increased risk for the development of a dangerous type of cancer than esophageal adenocarcinoma, currently First the fastest growing cancer in the U.S.Depending on the results from 5 x dose cohort and the independent statement which DMC trial, could randomized phase II trial with ProSavi the EU / States be introduced in 2012.. A further later doses of ProSavi is evaluated in the current six – group of patients, the graduated corresponds the optimum dose in preclinical studies to. Gene-based -month results from the first three patient in 5 times dose of cohort are in mid -2011 and be be published in H2 2011 after a validation check through the studies of Independent Data Monitoring Committee . Planner has underway for a sham – controlled, phase II clinical trial, the recruiting to up to 50 patients.

Stuart Naylor, Chief Scientific Officer of Oxford Biomedica, said:’the ProSavi record is very promising with respect to the improvements we is seeing about more endpoints with patient diaries action promote the positive influence on the lives of patients, information highlight the potential for this approach to address the motor symptoms of Parkinsons Disease. Develops We LentiVecto platform technology, on chronic degenerative diseases chronic degenerative diseases, and that ProSavi to treat results of Previously the long-term advantages manage administration.